Iron metabolism and its regulations

1. Sheftel AD, Mason AB, Ponka P. The long history of iron in the Universe and in health and disease. Biochim Biophys Acta 2012; 1820: 161–187.

2. Wächtershäuser G. On the chemistry and evolution of the pioneer organism. Chem Biodivers 2007; 4: 584–602.

3. Prentice AM. Hepcidin and iron-mediated resistance to malaria. EMBO Mol Med 2011; 3: 620–622.

4. McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol 1998; 35: 5–12.

5. Britton RS, Ramm GA, Olynyk J et al. Pathophysiology of iron toxicity. Adv Exp Med Biol 1994; 356: 239–253.

6. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997; 89: 1–25.

7. Babusiak M, Man P, Sutak R et al. Identification of heme binding protein complexes in murine erythroleukemic cells: study by a novel two-dimensional native separation – liquid chromatography and electrophoresis. Proteomics 2005; 5: 340–350.

8. Rouault TA. Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis Model Mech 2012; 5: 155–164.

9. Friedman A, Arosio P, Finazzi D et al. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord 2011; 17: 423–430.

10. Singh A, Mohan ML, Isaac AO et al. Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis. PLoS One 2009; 4: e4468.

11. Størmer FC, Wielgolaski FE. Are magnetite and ferritin involved in plant memory? Rev Environ Sci Biotechnolo 2010; 9: 105–107.

12. Størmer FC, Mysterud I, Slaqsvold T et al. Evolution and possible storage of information in a magnetite system of significance for brain development. Med Hypotheses 2011; 76: 901–904.

13. Tejada JA. Does macroscopic quantum coherence occur in ferritin? Science 1996; 272: 424–426.

14. Choi SH, Kim JW, Chu SH et al. Ferritin--Templated Quantum-Dots for Quantum Logic Gates. 12th SPIE International Symposium on Smart Structures and Smart Materials San Diego. California 2005: 3.6–3.10.

15. Hasan MR, Koikawa S, Kotani S et al. Ferritin forms dynamic oligomers to associate with microtubules in vivo: implication for the role of microtubules in iron metabolism. Exp Cell Res 2006; 312: 1950–1960.

16. Hagan S, Hameroff SR, Tuszyński JA. Quantum computation in brain microtubules: decoherence and biological feasibility. Phys Rev E Stat Nonlin Soft Matter Phys 2002; 65: 061901.

17. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161–203.

18. Chasteen ND. Ferritin. Uptake, storage, and release of iron. Metal Ions Biol Syst 1998; 35: 479–514.

19. Levi S, Corsi B, Bosisio M et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001; 276: 24437–24440.

20. Alkhateeb AA, Connor JR. Nuclear ferritin: a new role for ferritin in cell biology. Biochim Bio­phys Acta 2010; 1800: 793–797.

21. Richardson DR, Ponka P et al. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Bio­phys Acta 1997; 1331: 1–40.

22. Young SP, Bomford A, Williams R et al. The effect of the iron saturation of transferrin on its binding and uptake by rabbit reticulocytes. Biochem J 1984; 219: 505–510.

23. Kawabata H, Yang R, Hirama T et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826–20832.

24. Camaschella C, Roetto A, Calì A et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14–15.

25. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.

26. Feder JN, Tsuchihashi Z, Irrinki A et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997; 272: 14025–14028.

27. Gunshin H, Mackenzie B, Berger UV et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482–488.

28. Cannone-Hergaux F, Gruenheid S, Ponka P et al. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 1999; 12: 4406–4417.

29. Gruenheid S, Canonne-Hergaux F, Gauthier S et al. The iron transport protein NRAMP2 is an integral membrane glycoprotein that colocalizes with transferrin in recycling endosomes. J Exp Med 1999; 189: 831–841.

30. Fleming MD, Romano MA, Su MA et al. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci USA 1998; 95: 1148–1153.

31. Fleming MD, Trenor CC 3rd, Su MA et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16: 383–386.

32. Mims MP, Guan Y, Pospisilova D et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005; 105: 1337–1342.

33. Mukhopadhyay CK, Attieh ZK, Fox PL et al. Role of ceruloplasmin in cellular iron uptake. Science 1998; 279: 714–717.

34. Harris ZL, Durley AP, Man TK et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999; 96: 10812–10817.

35. Vulpe CD, Kuo YM, Murphy TL et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999; 21: 195–199.

36. Donovan A, Brownlie A, Zhou Y et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776–781.

37. McKie AT, Marciani P, Rolfs A et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299–309.

38. Njajou OT, Vaessen N, Joosse M et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213–214.

39. Patel PI, Isaya G. Friedreich ataxia: from GAA triplet-repeat expansion to frataxin defi­ciency. Am J Hum Genet 2001; 69: 15–24.

40. Sutak R, Xu X, Whitnall M et al. Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism. Proteomics 2008; 8: 1731–1741.

41. Lim JE, Jin O, Bennett C et al. A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet 2005; 37: 1270–1273.

42. Cmejla R, Ptackova P, Petrak J et al. Human MRCKalpha is regulated by cellular iron levels and interferes with transferrin iron up­take. Biochem Biophys Res Commun 2010; 395: 163–167.

43. Cmejla R, Petrak J, Cmejlova J. A novel iron responsive element in the 3‘UTR of human MRCKalpha. Biochem Biophys Res Commun 2006; 341: 158–166.

44. Heikkila T, Wheatley E, Crighton D et al. Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion. PLoS One 2011; 6: e24825.

45. Aisen P. Transferrin, the transferrin receptor, and the uptake of iron by cells. Metal Ions Biol Syst 1998; 35: 585–631.

46. Knutson MD. Steap proteins: implications for iron and copper metabolism. Nutr Rev 2007; 65: 335–340.

47. Vyoral D, Hradilek A, Neuwirt J. Transferrin and iron distribution in subcellular fractions of K562 cells in the early stages of transferrin endocytosis. Biochim Biophys Acta 1992; 137: 148–154.

48. Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 1996; 87: 3477–3488.

49. Vyoral D, Petrák J. Iron transport in K562 cells: a kinetic study using native gel electrophoresis and 59Fe autoradiography. Biochim Biophys Acta 1998; 1403: 179–188.

50. Petrák JV, Vyoral D. Detection of iron-containing proteins contributing to the cellular labile iron pool by the native electrophoresis metal blotting technique. J Inorg Biochem 2001; 86: 669–675.

51. O’Halloran TV, Culotta VC. Metallochaperones, an intracellular shuttle service for metal ions. J Biol Chem 2000; 275: 25057–25060.

52. Sheftel AD, Zhang AS, Brown C et al. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood 2007; 110: 125–132.

53. Theil CE. The iron responsive element (IRE) family of mRNA regulators. Regulation of iron transport and uptake compared in animals, plants, and microorganisms. Met Ions Biol Syst 1998; 35: 403–434.

54. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol 1998; 35: 35–54.

55. Uzel C, Conrad ME. Absorption of heme iron. Semin Hematol 1998; 35: 27–34.

56. Worthington MT, Cohn SM, Miller SK et al. Characterization of a human plasma membrane heme transporter in intestinal and hepatocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1172–G1177.

57. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001; 98: 8160–8162.

58. Hershko C, Peto TE. Non-transferrin plasma iron. Br J Haematol 1987; 66: 149–151.

59. Hershko C, Graham G, Bates GW et al. Non--specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255–263.

60. Bradley SJ, Gosriwitana I, Srichairatanakool S et al. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997; 99: 337–343.

61. Grootveld M, Bell JD, Halliwell B et al. Non--transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem 1989; 264: 4417–4422.

62. Richardson D, Baker E. The uptake of inorganic iron complexes by human melanoma cells. Biochim Biophys Acta 1991; 1093: 20–28.

63. Kaplan J, Jordan I, Sturrock A et al. Regulation of the transferrin-independent iron transport system in cultured cells. J Biol Chem 1991; 266: 2997–3004.

64. Sturrock A, Alexander J, Lamb J et al. Characterization of a transferrin-independent uptake system for iron in HeLa cells. J Biol Chem 1990; 265: 3139–3145.

65. Basset P, Quesneau Y, Zwiller J. Iron-induced L1210 cell growth: evidence of a transferrin-independent iron transport. Cancer Res 1986; 46: 1644–1647.

66. Krause A, Neitz S, Mägert HJ et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480: 147–150.

67. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806–7810.

68. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780–8785.

69. Nicolas G, Bennoun M, Porteu A et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596–4601.

70. Roetto A, Papanikolaou G, Politou M et al. Mutant antimicrobial peptide hepcidin is asso­ciated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21–22.

71. Schwarz P, Kübler JA, Strnad P et al. Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by Helicobacter pylori infection. Gut 2012; 61: 193–201.

72. Strnad P, Schwarz P, Rasenack MC et al. Hepcidin is an antibacterial, stress-inducible peptide of the biliary system. PLoS One 2011; 6: e16454.

73. Kulaksiz H, Fein E, Redecker P et al. Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol 2008; 197: 241–249.

74. Li JJ, Meng X, Si HP et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterio­scler Thromb Vasc Biol 2012; 32: 1158–1166.

75. Simonis G, Mueller K, Schwarz P et al. The iron-regulatory peptide hepcidin is upregulated in the ischemic and in the remote myocardium after myocardial infarction. Peptides 2010; 31: 1786–1790.

76. Oliveira SJ, de Sousa M, Pinto JP. ER Stress and Iron Homeostasis: A New Frontier for the UPR. Biochem Res Int 2011: 896474.

77. De Domenico I, Zhang TY, Koening CL et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010; 120: 2395–2405.

78. Duru S, Bilgin E, Ardiç S. Hepcidin: A useful marker in chronic obstructive pulmonary disease. Ann Thorac Med 2012; 7: 31–35.

79. Patent WO2009139822.

80. Kroot JJ, Tjalsma H, Fleming RE et al. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011; 57: 1650–1669.

81. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron--restricted erythropoiesis. Blood 2010; 116: 4754–4761.

82. Sasu BJ, Cooke KS, Arvedson TL et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115: 3616–3624.

83. Bartnikas TB, Fleming MD. A tincture of hepcidin cures all: the potential for hepcidin therapeutics. J Clin Invest 2010; 120: 4187–4190.

84. Li H, Rose MJ, Tran L et al. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods 2009; 59: 171–180.

85. Peslova G, Petrak J, Kuzelova K et al. Hepcidin the hormone of iron metabolism is bound to alpha-2-macroglobulin in blood. Blood 2009; 113: 6225–6236.

86. Richardson DR, Kalinowski DS, Lau S et al. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 2009; 1790: 702–717.

87. Torti SV, Torti FM. Ironing out cancer. Cancer Res 2011; 71: 1511–1514.

88. Pinnix ZK, Miller LD, Wang W et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010; 2: 43–56.

89. Merlot AM, Kalinowski DS, Richardson DR. Novel Chelators for Cancer Treatment: Where are we Now? Antioxid Redox Signal 2012. Epub ahead of print.

90. Pietrangelo A. Hepcidin in human iron dis­orders: therapeutic implications. J Hepatol 2011; 54: 173–181.